Method for activation treatment of antigen-presenting cell

A technology for activation treatment and cells, applied in biochemical equipment and methods, receptors/cell surface antigens/cell surface determinants, antibacterial drugs, etc.

Active Publication Date: 2008-09-03
迈世耐特股份公司
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] However, the increase in the induction of disease antigen-specific CTLs by the direct adjuvant effect via TLRs or the indirect adjuvant effect via immunocompetent cells other than disease antigen-specific CTLs was compared to the case where these adjuvants were not used. , about 4 to 6 times (in vitro)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for activation treatment of antigen-presenting cell
  • Method for activation treatment of antigen-presenting cell
  • Method for activation treatment of antigen-presenting cell

Examples

Experimental program
Comparison scheme
Effect test

no. 1 approach

[0063] First Embodiment: Production of Activated Antigen Presenting Cells

[0064] First, the activated antigen-presenting cells of the present invention will be described in detail.

[0065] The activated antigen-presenting cells of the present invention refer to antigen-presenting cells co-sensitized with a bisphosphonic acid compound and a disease antigen.

[0066] The antigen-presenting cells used in the present invention are not particularly limited, and for example, any of immature dendritic cells, mature dendritic cells, other antigen-presenting cells, artificial antigen-presenting cells, and mixtures thereof can be used. Among them, immature dendritic cells and mature dendritic cells are preferred, and immature dendritic cells are more preferred. This is due to the fact that immature dendritic cells may be better suited to induce disease antigen-specific CTLs and / or γδ T cells when co-sensitized with bisphosphonates and disease antigens. In addition, the aforementi...

no. 2 approach

[0097] Second Embodiment: Drugs Containing Activated Antigen Presenting Cells of the Present Invention

[0098] Next, the drug using activated antigen-presenting cells of the present invention will be described based on an example of using dendritic cells as antigen-presenting cells in the same manner as above.

[0099] First, the activated antigen-presenting cells (activated dendritic cells) obtained in the first embodiment described above are recovered by centrifugation or the like. Next, the recovered cells are washed. As the washing liquid, any liquid can be used as long as it is isotonic and can be used as a medicine. Thereafter, in consideration of administration to patients, physiological saline, PBS, and the like are preferably used. Furthermore, the recovered dendritic cells can be used as medicines by suspending them in physiological saline. In addition, serum components such as albumin or cytokines may be added as needed. In particular, the drug is preferably ...

no. 3 approach

[0100] Third Embodiment: Therapeutic and preventive methods using activated antigen-presenting cells of the present invention Law

[0101] Next, the method of treatment and prevention using dendritic cells of the present invention will be described based on an example of using dendritic cells as antigen-presenting cells in the same manner as above.

[0102] Cancer and / or infectious diseases can be treated and prevented by administering the activated antigen-presenting cells (activated dendritic cells) of the present invention obtained in the first embodiment above or the drug of the present invention obtained in the second embodiment.

[0103] The number of cells to be administered can be appropriately selected according to the method of administration and the condition of the patient, and is not particularly limited. Usually each dose is preferably 10 6 ~10 8 person / person, more preferably 10 7 One / person or more. The frequency of administration varies depending on th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

An activated antigen-presenting cell capable of inducing an immunocompetent cell including a disease antigen-specific CD8+CTL and / or a gamma delta T cell in vivo and / or in vitro with good efficiency; a pharmaceutical comprising the activated antigen-presenting cell; a therapeutic / prophylactic method using the activated antigen-presenting cell; a method for induction of an immunocompetent cell including a disease antigen-specific CD8+CTL and / or a gamma delta T cell which is induced by using the activated antigen-presenting cell; an immunocompetent cell induced by the method; a pharmaceutical comprising the immunocompetent cell; and a therapeutic / prophylactic method using the immunocompetent cell. An antigen-presenting cell is sensitized with a disease antigen and also co-sensitized with bisphosphonate, thereby producing an increased number of a disease antigen-specific CD8+CTL and / or a gamma delta T cell at a higher ratio compared to a method without co-sensitization with bisphosphonate.

Description

technical field [0001] The present invention relates to antigen presenting cells obtained by co-sensitization with bisphosphonate and disease antigens. In addition, the present invention relates to medicines containing the antigen-presenting cells, methods of treatment and prevention using the dendritic cells, and methods of inducing immunocompetent cells using the antigen-presenting cells. Furthermore, the present invention relates to immunocompetent cells induced by the induction method, pharmaceuticals containing the immunocompetent cells, and therapeutic and preventive methods using the immunocompetent cells. Background technique [0002] As cancer therapy, excision by surgery, radiation, and chemotherapy using anticancer agents have been performed. In recent years, various treatment methods other than these treatments have been researched and put into practical use. One of them is immune cell therapy using immune cells. [0003] Immune cell therapy includes LAK (lymp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N5/06A61P31/00A61K35/12A61P35/00A61K31/663A61K35/15C07K14/705C07K14/82C12N5/071C12N5/0783C12N5/0784C12N5/0786
CPCA61K39/0011C12N5/0639C12N5/0636A61K2039/5158A61K38/00A61P31/00A61P31/04A61P35/00A61K39/4615A61K2239/57A61K39/4622A61K39/464491A61K39/464838A61K35/12
Inventor 贄田美江矶贝真奈美高原将司A·尼科尔
Owner 迈世耐特股份公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap